gemcitabine has been researched along with silodosin in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Aljarah, AK; Han, B; Ide, H; Inoue, S; Kashiwagi, E; Kawahara, T; Li, Y; Miyamoto, H; Patterson, JD; Shareef, HK; Zheng, Y | 1 |
1 review(s) available for gemcitabine and silodosin
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
1 other study(ies) available for gemcitabine and silodosin
| Article | Year |
|---|---|
Silodosin inhibits prostate cancer cell growth via ELK1 inactivation and enhances the cytotoxic activity of gemcitabine.
Topics: Adrenergic alpha-1 Receptor Antagonists; Antineoplastic Agents; Cell Line, Tumor; Cell Movement; Cell Proliferation; Deoxycytidine; Drug Interactions; ets-Domain Protein Elk-1; Gemcitabine; Gene Silencing; Humans; Indoles; Male; Neoplasm Invasiveness; Phosphorylation; Prostate; Prostatectomy; Prostatic Neoplasms; Proto-Oncogene Mas; Receptors, Androgen | 2016 |